Hemophilia Market Share, Size from 2021 to 2025: Import-Export, Industry Chain Structure and Development Opportunities

REPORT HIGHLIGHT

The hemophilia market is estimated to represent a global market of USD 10.23 billion by 2017 with growth rate of 5.3%.

Market Dynamics

Over the eight years to 2016, revenue for the hemophilia industry is anticipated trend higher. Increasing neonatal population is expected to drive the hemophilia diagnosis demand globally. The World Population Meter stated that more than 88.0 billion newborns were reported in 2015 resulting in about 250 births per minute. Of which, approximately 2.8 million infants died within the first month, due to lack of skilled care and proper screening of the babies. The World Health Organization (WHO) also stated that around 2.6 million children died in their first month of life across the globe, which is 7,000 newborn deaths every day. In addition, strong product pipeline will further stimulate the industry growth to great extent over the future period. For example, N9-GP, Concizumab, N8-GP, and Recombinant factor VIIa are some of the bleeding disorder therapeutics under clinical investigations by Novo Nordisk. Despite the industry pipeline increasing, some potential threats exist which will likely to hinder growth prospects going forward. Factors such as high treatment cost coupled with low acceptance of advanced technologies are posing a potential threat to the market.

Download  Sample of This Strategic Report-https://www.kennethresearch.com/sample-request-10293919

Types Takeaway

In terms of types, the market is categorized into A, B, C, and other types. Type A accounted for the highest share of the total market. In 2017, the segment recorded 6.8 billion and is expected to dominate the global market over the forecast period. This type is acquired due to the deficiency of clotting factor VIII, which is an anti-hemophilic factor (AHF). According to the National Hemophilia Foundation (NHF), 1 in 5,000 male population affect with type A disorder, which makes it four times more common compared to the type B. As per the Hemophilia News Today, around 4,000 to 5,000 males are affected with type A disease worldwide. Markets besides hemophilia A, B & C is expected to generate the remaining 5.0% of market revenue in 2017.

Treatment Takeaway

The treatment segment is divided into On-demand and Prophylaxis. Inpatient with mild to severe hemophilia, treatment is being given at the time when bleeding occurs which is termed as on-demand therapy. The on-demand treatment industry is in the mature phase and is projected to grow with a significant growth rate over the foreseeable future. Depending upon therapy, the market is segmented as Immune Tolerance Induction (ITI), Replacement, and Gene therapy. Replacement therapy captures a major chunk of the global revenue. This method is performed through the infusion of factor VIII and IX concentrates to prevent bleeding. On contrary, gene therapy is considered to be the lowest revenue generating segment, generated less than 1% revenue in 2017. Most of the gene therapies for hemophilia treatment are under clinical studies and likely attract greater demand during the future period.

Key Vendor Takeaway

Companies namely, Novo Nordisk, Bayer AG, Pfizer, Inc., Baxalta, and Biogen are profiled. In light of more players entering in this market. the degree of competition has intensified over a couple of years. Competition is based on the development of new therapeutics and co-pay programs.

Request For Full Report-https://www.kennethresearch.com/sample-request-10293919

For example, Grifols provide co-pay programs such as ALPHANATE Copay Program and AlphaNine SD Copay card for this bleeding disorder treatment with an unlimited monetary limit. In addition, companies are engaged in donation activities with government organizations. For instance, in 2016, the World Federation of Hemophilia collected 1.5 million units of anti-hemophilic agents from CSL Behring as a donation on World Hemophilia Day.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2014 & 2016

Base Year – 2017

Estimated Year – 2018

Projected Year – 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY TYPES

Hemophilia A

Hemophilia B

Hemophilia C

Others

MARKET, BY TREATMENT

On-demand

Prophylaxis

MARKET, BY THERAPY

Immune Tolerance Induction (ITI) therapy

Replacement therapy

Gene therapy

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Name: Kenneth research

Email:sales@kennethresearch.com

Phone: +1 313 462 0609